Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
(2025) In JAMA Network Open 8(7).- Abstract
- Importance: Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood. Objective: To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes. Design, Setting, and Participants: This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective... (More)
- Importance: Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood. Objective: To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes. Design, Setting, and Participants: This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024. Exposure: MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use). Main Outcomes and Measures: Breast cancer intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched-like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5- (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/cc05dc32-a04c-4f4d-9462-87102202e3b2
- author
- Le Cornet, C. ; Jernström, H. LU ; Augustinsson, A. LU and Chang-Claude, J.
- author collaboration
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Aged, Breast Neoplasms, Case-Control Studies, Contraceptives, Oral, Estrogen Replacement Therapy, Female, Humans, Middle Aged, Postmenopause, Premenopause, Prospective Studies, oral contraceptive agent, adult, adverse event, aged, breast tumor, case control study, classification, epidemiology, estrogen therapy, female, human, middle aged, pathology, postmenopause, premenopause, prospective study
- in
- JAMA Network Open
- volume
- 8
- issue
- 7
- article number
- e2519236
- publisher
- American Medical Association
- external identifiers
-
- scopus:105010665632
- pmid:40622713
- ISSN
- 2574-3805
- DOI
- 10.1001/jamanetworkopen.2025.19236
- language
- English
- LU publication?
- yes
- additional info
- Number of authors = 57 EID = 105010665632 Start page = e2519236 Affiliation = Le Cornet C., Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany Affiliation = Fortner R.T., Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany, Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway Affiliation = Chang-Claude J., Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany, Cancer Epidemiology Group, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany
- id
- cc05dc32-a04c-4f4d-9462-87102202e3b2
- date added to LUP
- 2026-03-18 14:01:51
- date last changed
- 2026-03-19 03:00:01
@article{cc05dc32-a04c-4f4d-9462-87102202e3b2,
abstract = {{Importance: Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood. Objective: To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes. Design, Setting, and Participants: This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024. Exposure: MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use). Main Outcomes and Measures: Breast cancer intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched-like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-}},
author = {{Le Cornet, C. and Jernström, H. and Augustinsson, A. and Chang-Claude, J.}},
issn = {{2574-3805}},
keywords = {{Adult; Aged; Breast Neoplasms; Case-Control Studies; Contraceptives, Oral; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Postmenopause; Premenopause; Prospective Studies; oral contraceptive agent; adult; adverse event; aged; breast tumor; case control study; classification; epidemiology; estrogen therapy; female; human; middle aged; pathology; postmenopause; premenopause; prospective study}},
language = {{eng}},
number = {{7}},
publisher = {{American Medical Association}},
series = {{JAMA Network Open}},
title = {{Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer}},
url = {{http://dx.doi.org/10.1001/jamanetworkopen.2025.19236}},
doi = {{10.1001/jamanetworkopen.2025.19236}},
volume = {{8}},
year = {{2025}},
}